FERRO SOLUTIONS, INC. — Department of Health and Human Services SBIR Phase II: NINDS
FERRO SOLUTIONS, INC. — SBIR Phase II award from Department of Health and Human Services.
- Amount
- $2,946,849
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Topic
- NINDS
- Solicitation
- PA12-088
- NAICS
- —
- Place of performance
- MA
- Period
- 2013-08-01 → 2016-07-31
Description
<p>DESCRIPTION provided by applicant Optogenetic tools for activating and silencing specific neurons embedded within dense brain networks in a temporally precise fashion using light are key to understanding the roles that specific neurons play in behavior neural computation and disease In our Phase I SBIR Ferro Solutions and the Boyden lab at MIT collaborated to develop a fully wirelessly powered and wirelessly controlled headborne device small enough to be carried on a mouse head and containing an array of multiple blue LEDs for direct stimulation of surface structures In our Phase II SBIR we propose to extend this device with a number of new capabilities thus creating a powerful and easy to use toolbox to support a large range of optogenetics experiments both for empowering basic science researchers and as prototypes of future clinical devices Specifically we propose to add new light sources add wireless targeting of deep structures and improve the power and range of the system The system will be of utility to scientists working with mice and rats to study neural circuits and to clinicians as prototypes of optical neural control prosthetics We will work to make our devices available and easy to use by scientists and clinicians in academia and industry PUBLIC HEALTH RELEVANCE The ability to treat brain disorders relies on accurately finding targets in the brain that can serve as targets for novel drugs or for electrical stimulation We are developing a wireless high throughput toolbox that enables basic and applied scientists to hunt down the targets in the brain that most efficaciously treat brain disorders while minimizing side effects We anticipate broad use of these tools in pre clinical settings where they will empower investigators of neurological and psychiatric disorders</p>